ALVAC-HIV elicits V2, V3, and CD4 inducible (CD4i) binding antibody responses. by LaTonya D. Williams (3140490)

Dynamics of 25 year Teletherm dates, periods, extents, and temperatures for three example locations displaying abrupt switchings in time and gradual increases and decreases of temp... by Peter Sheridan Dodds (188891)

Early Stages of Sea-Level Rise Lead To Decreased Salt Marsh Plant Diversity through Stronger Competition in Mediterranean-Climate Marshes - Fig 2 by Akana E. Noto (3623366)

Exercise training decreases 4-HNE modification of proteasome and re-establishes cardiac ubiquitin-proteasome system function in myocardial infarction-induced heart failure. by Juliane C. Campos (145308)

Reduction of the mean absolute error (MAE) in time for all participant on x-axis. by Almoctar Hassoumi (6470354)

“…<p>A similar effect is observed for y-axis. The MAE obtained using the standard regression (orange circles) decreased significantly when using symbolic regression. …”

Psoriatic lesion in some of the hard-to-treat areas of the study population. by Dina Evyana (18462048)

Delayed boosting with ALVAC-HIV/AIDSVAX B/E or AIDSVAX B/E increases breadth of Env-specific IgG response. by LaTonya D. Williams (3140490)

Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

“…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC₅₀ at 2.1 μM. …”

Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

“…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC₅₀ at 2.1 μM. …”

Image1_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

“…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”

Image2_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

“…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”

Image3_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

“…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”

Image4_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

“…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”

Image5_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

“…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”

Discovery of Urea Derivatives of Celastrol as Selective Peroxiredoxin 1 Inhibitors against Colorectal Cancer Cells by Yang Li (7082)

“…Herein, a series of celastrol urea derivatives were developed based on its cocrystal structure with PRDX1, with the aim of pursuing a PRDX1-specific inhibitor. …”

Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases by Xiao Li (107004)

“…Compared to the type I PRMT inhibitor from our previous work (DCPR049_12), ZL-28-6 showed increased potency against CARM1 and decreased activity against other type I PRMTs. Moreover, ZL-28-6 showed better antiproliferation activities toward a series of solid tumor cells than DCPR049_12, indicating its broad spectrum of anticancer activity. …”

Association of metabolic syndrome and psoriasis severity. by Dina Evyana (18462048)

Sociodemographic characteristic of the study population. by Dina Evyana (18462048)

Baseline clinical characteristic of the study population. by Dina Evyana (18462048)

Prevalence of metabolic syndrome (MetS) in hard-to-treat psoriasis. by Dina Evyana (18462048)